tarsus pharmaceuticals inc. - TARS
TARS
Close Chg Chg %
47.57 -1.07 -2.24%
Closed Market
46.51
-1.07 (2.24%)
Volume: 857.86K
Last Updated:
Nov 13, 2024, 4:00 PM EDT
Company Overview: tarsus pharmaceuticals inc. - TARS
TARS Key Data
| Open $47.60 | Day Range 46.22 - 48.83 |
| 52 Week Range 15.60 - 51.59 | Market Cap $1.81B |
| Shares Outstanding 38.04M | Public Float 31.79M |
| Beta 1.00 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$4.48 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 931.96K |
TARS Performance
| 1 Week | -5.90% | ||
| 1 Month | 30.23% | ||
| 3 Months | 81.02% | ||
| 1 Year | 146.58% | ||
| 5 Years | N/A |
TARS Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About tarsus pharmaceuticals inc. - TARS
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
TARS At a Glance
Tarsus Pharmaceuticals, Inc.
15440 Laguna Canyon Road
Irvine, California 92618
| Phone | 1-949-409-9820 | Revenue | 17.45M | |
| Industry | Pharmaceuticals: Major | Net Income | -135,893,000.00 | |
| Sector | Health Technology | Employees | 244 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
TARS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 34.104 |
| Price to Book Ratio | 3.517 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.806 |
| Enterprise Value to Sales | 22.887 |
| Total Debt to Enterprise Value | 0.079 |
TARS Efficiency
| Revenue/Employee | 71,504.098 |
| Income Per Employee | -556,938.525 |
| Receivables Turnover | 0.985 |
| Total Asset Turnover | 0.071 |
TARS Liquidity
| Current Ratio | 6.934 |
| Quick Ratio | 6.85 |
| Cash Ratio | 6.158 |
TARS Profitability
| Gross Margin | 90.869 |
| Operating Margin | -820.531 |
| Pretax Margin | -778.89 |
| Net Margin | -778.89 |
| Return on Assets | -55.008 |
| Return on Equity | -69.709 |
| Return on Total Capital | -59.415 |
| Return on Invested Capital | -61.67 |
TARS Capital Structure
| Total Debt to Total Equity | 16.109 |
| Total Debt to Total Capital | 13.874 |
| Total Debt to Total Assets | 11.919 |
| Long-Term Debt to Equity | 15.907 |
| Long-Term Debt to Total Capital | 13.70 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Tarsus Pharmaceuticals Inc. - TARS
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 57.03M | 25.82M | 17.45M | |
Sales Growth
| - | - | -54.73% | -32.42% | - |
Cost of Goods Sold (COGS) incl D&A
| 246.00K | 2.08M | 955.00K | 1.59M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 246.00K | 606.00K | 789.00K | 877.00K | |
Depreciation
| 246.00K | 606.00K | 789.00K | 744.00K | |
Amortization of Intangibles
| - | - | - | 133.00K | - |
COGS Growth
| +232.43% | +743.50% | -53.98% | +66.81% | |
Gross Income
| (246.00K) | 54.95M | 24.86M | 15.85M | |
Gross Income Growth
| -232.43% | +22,438.21% | -54.76% | -36.23% | |
Gross Profit Margin
| - | +96.36% | +96.30% | +90.87% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 26.74M | 67.11M | 87.57M | 159.01M | |
Research & Development
| 18.81M | 41.71M | 42.62M | 50.31M | |
Other SG&A
| 7.93M | 25.40M | 44.95M | 108.70M | |
SGA Growth
| +532.98% | +151.00% | +30.49% | +81.58% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 15.00K | 1.58M | 769.00K | (376.00K) | |
EBIT after Unusual Expense
| (27.00M) | (13.73M) | (63.48M) | (142.78M) | |
Non Operating Income/Expense
| 188.00K | (37.00K) | 3.58M | 10.23M | |
Non-Operating Interest Income
| 188.00K | 36.00K | 3.50M | 10.34M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 2.20M | 3.35M | - |
Interest Expense Growth
| - | - | -100.00% | +52.16% | - |
Gross Interest Expense
| - | - | 2.20M | 3.35M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (26.81M) | (13.77M) | (62.09M) | (135.89M) | |
Pretax Income Growth
| -474.21% | +48.63% | -350.88% | -118.85% | |
Pretax Margin
| - | -24.15% | -240.53% | -778.89% | |
Income Tax
| - | 1.00K | 55.00K | (4.00K) | |
Income Tax - Current - Domestic
| - | - | - | (4.00K) | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (26.81M) | (13.83M) | (62.09M) | (135.89M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (26.81M) | (13.83M) | (62.09M) | (135.89M) | |
Net Income Growth
| -474.11% | +48.43% | -349.06% | -118.86% | |
Net Margin Growth
| - | -24.25% | -240.51% | -778.89% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (26.81M) | (13.83M) | (62.09M) | (135.89M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (26.81M) | (13.83M) | (62.09M) | (135.89M) | |
EPS (Basic)
| -1.3192 | -0.6727 | -2.522 | -4.6248 | |
EPS (Basic) Growth
| -451.04% | +49.01% | -274.91% | -83.38% | |
Basic Shares Outstanding
| 20.32M | 20.55M | 24.62M | 29.38M | |
EPS (Diluted)
| -1.3192 | -0.6727 | -2.522 | -4.6248 | |
EPS (Diluted) Growth
| -451.04% | +49.01% | -274.91% | -83.38% | |
Diluted Shares Outstanding
| 20.32M | 20.55M | 24.62M | 29.38M | |
EBITDA
| (26.74M) | (11.55M) | (61.92M) | (142.28M) | |
EBITDA Growth
| -532.98% | +56.80% | -436.08% | -129.77% | |
EBITDA Margin
| - | -20.26% | -239.86% | -815.50% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 59.25 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.949 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -3.795 | |
| Last Quarter’s Earnings | -0.61 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -4.62 | Next Fiscal Year Estimate | -2.159 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 5 | 8 | 7 |
| Mean Estimate | -0.95 | -0.86 | -3.80 | -2.16 |
| High Estimates | -0.78 | -0.72 | -3.48 | -0.81 |
| Low Estimate | -1.21 | -0.98 | -4.21 | -3.90 |
| Coefficient of Variance | -16.29 | -12.29 | -6.44 | -44.40 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 7 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Tarsus Pharmaceuticals Inc. - TARS
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Tarsus Pharmaceuticals Inc. - TARS
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jun 26, 2024 | Rosemary A. Crane Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Elizabeth Yeu-Lin Director | 5,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Elizabeth Yeu-Lin Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Scott William Morrison Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Scott William Morrison Director | 4,683 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Andrew D. Goldberg Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Andrew D. Goldberg Director | 6,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | William J. Link Director | 139,982 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Rosemary A. Crane Director | 5,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Bhaskar Chaudhuri Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Bhaskar Chaudhuri Director | 5,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Wendy L. Yarno Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | Wendy L. Yarno Director | 10,350 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 26, 2024 | William J. Link Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 21, 2024 | Jeffrey S. Farrow See Remarks | 83,644 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jun 21, 2024 | Jeffrey S. Farrow See Remarks | 18,136 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.47 per share | 498,195.92 |
| Jun 21, 2024 | Jeffrey S. Farrow See Remarks | 28,581 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 20, 2024 | Bobak Azamian President/CEO and Board Chair; Director | 36,871 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 20, 2024 | Bobak Azamian President/CEO and Board Chair; Director | 26,456 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $30.6 per share | 809,553.60 |
| Mar 20, 2024 | Bobak Azamian President/CEO and Board Chair; Director | 22,599 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |